drugset / Trial / NCT01631422

A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers

NCT01631422

Phase 1 Completed 6 enrolled Hoffmann-La Roche
Non-randomizedSingle-groupOpen-label

Summary

This single-center, open-label study will investigate the pharmacokinetics and elimination of a radiolabelled dose of RO4602522 in healthy male volunteers. The healthy male volunteers will receive a single oral dose of RO4602522.

Timeline

Start
2012-06
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject RO4602522 Unknown Oral

Indications

No indication recorded.